CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 2 filers reported holding CHINOOK THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $563,934 | 0.0% | 24,360 | 0.0% | 0.00% | – |
Q1 2023 | $563,934 | -36.0% | 24,360 | -27.5% | 0.00% | – |
Q4 2022 | $880,792 | -99.8% | 33,618 | +17.8% | 0.00% | – |
Q3 2022 | $561,136,000 | +112.3% | 28,542 | +88.9% | 0.00% | – |
Q2 2022 | $264,256,000 | – | 15,109 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 5,161,888 | $198,319,737 | 34.81% |
Saturn V Capital Management LP | 524,811 | $20,163,239 | 11.18% |
Frazier Life Sciences Management, L.P. | 4,345,559 | $166,956,377 | 9.97% |
Altium Capital Management LP | 305,000 | $11,718,100 | 8.87% |
MPM BioImpact LLC | 1,003,406 | $38,550,859 | 7.76% |
Affinity Asset Advisors, LLC | 321,017 | $12,333,473 | 4.31% |
ALPINE ASSOCIATES MANAGEMENT INC. | 2,131,000 | $81,873,020 | 3.69% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,748,141 | $67,163,577 | 3.59% |
Nan Fung Group Holdings Ltd | 113,950 | $4,377,959 | 2.80% |
Vivo Capital, LLC | 934,879 | $35,918,051 | 2.48% |